PFE יחס מחיר להכנסות חזויות Pfizer Inc

Pfizer Inc. (PFE) leverages its colossal capital to acquire biotech startups and establish monopoly pricing. The forward P/S history on GURU.Markets reflects a turning point driven by generic pressure and patent battles, although a stable brand image continues to support the company. The current 0.60 metric confirms investor expectations for future revenue amid stringent regulatory policies.

To minimize risks when constructing a long-term portfolio, it is critical to align market capitalization with expected sales volumes. In the case of Pfizer Inc. (PFE), the integration of Seagen and the oncology pipeline update must offset the revenue decline from COVID-19 products. By analyzing the future P/S multiple on the GURU.Markets platform, an investor assesses the value of each unit of future revenue, which allows for an objective confirmation of the business's fundamental stability.